pharmaceutical investing Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
Homerun Resources Inc. Files for Approval of $3 Million Financing; Updates $6 Million Institutional Financing
